EFTR Company Profile and Key Details

Q: Who are the executives of EFTR?

Dr. Douglas Warner M.D.Chief Medical OfficerDr. Stephen T. Worland Ph.D.Chief Executive Officer, Pres & DirectorMr. Michael Byrnes M.B.A.Chief Financial OfficerDr. Davide Ruggero Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Mayank J. Gandhi M.D.Chief Bus. OfficerDr. Siegfried Reich Ph.D.Co-Founder and Member of Clinical & Scientific Advisory Board

NASDAQ : EFTR

eFFECTOR Therapeutics

$0.00

-0.0005-62.50%

At Close 4:00 PM

71.82

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

eFFECTOR Therapeutics, Inc. (EFTR) stock declined over -62.50%, trading at $0.00 on OTC, down from the previous close of $0.00. The stock opened at $0.00, fluctuating between $0.00 and $0.00 in the recent session.

Stock Snapshot

0.0008

Prev. Close

1.41K

Market Cap

0.0002

Day Low

N/A

P/E Ratio

-13.08

EPS (TTM)

-11.1

Cash Flow per Share

Open

4.7M

Number of Shares

0.0003

Day High

99%

Free Float in %

-2.17

Book Value

331

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Aug 21, 2026	0.00	0.00	0.00	0.00	112.14K
Aug 18, 2026	0.00	0.00	0.00	0.00	135
Aug 13, 2026	0.00	0.00	0.00	0.00	186
Jul 29, 2026	0.00	0.00	0.00	0.00	181
Jul 24, 2026	0.00	0.00	0.00	0.00	264
Jul 23, 2026	0.00	0.00	0.00	0.00	2.67K
Jul 20, 2026	0.00	0.00	0.00	0.00	400
Jul 15, 2026	0.00	0.00	0.00	0.00	3.61K
Jul 14, 2026	0.00	0.00	0.00	0.00	10.04K
Jul 06, 2026	0.00	0.00	0.00	0.00	1K
Jun 29, 2026	0.00	0.00	0.00	0.00	250
Jun 26, 2026	0.00	0.00	0.00	0.00	17.97K
Jun 18, 2026	0.00	0.00	0.00	0.00	1.1K
Jun 16, 2026	0.00	0.00	0.00	0.00	310
Jun 08, 2026	0.00	0.00	0.00	0.00	978
Jun 05, 2026	0.00	0.00	0.00	0.00	2.64K
Jun 03, 2026	0.00	0.00	0.00	0.00	500
Jun 01, 2026	0.00	0.00	0.00	0.00	476
May 29, 2026	0.00	0.00	0.00	0.00	3.52K
May 28, 2026	0.00	0.00	0.00	0.00	807

Contact Details

Solana Beach, CA 92075

United States

https://effector.com 858 925 8215

About Company

eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.

Stock Peers

LZAGF

-5-0.92%

Lonza Group AG$541.00 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 LZAGY

-0.33-0.61%

Lonza Group AG$53.87 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 GRTX

1.53+9.80%

Galera Therapeutics, Inc.$17.15 NURPF

Neuren Pharmaceuticals Limited$14.00

Company Overview

The stock is currently mid-range between its 52-week high and low $0.00 and $0.01. With a market capitalization of about $1.41 thousand, eFFECTOR Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.44). Key stats such as the average daily volume over the past year has been around 2.59 thousand shares, volume is running light vs its 52-week average. Headquartered in Solana Beach, CA, eFFECTOR Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Craig R. Jalbert, the company employs approximately 14 people and listed since March 01, 2021. eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers.

Technical Performance

EFTR has shown weak momentum, losing -13.55% over the past week and -97.55% over the past quarter, though year-to-date performance is down -89.83%. Short-term trend indicators are bullishly aligned (SMA20 -21.66%, SMA50 -94.14%, SMA200 -99.48%). The stock’s 14-day RSI is 16.84 (weak momentum), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.8% below its high and over 29.69% above its low. Average 10-day trading volume of 56.14 thousand shares is significantly above the 3-month average of 7.61 thousand, indicating heightened recent market interest.

Valuation Metrics

eFFECTOR Therapeutics, Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at -0.0, also above market averages.

Dividend & Fair Value

eFFECTOR Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.09. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of -$4.25. The next quarter is forecast at -$2.02. Next year's EPS is expected at $29.26. eFFECTOR Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 13, 2024, missed forecasts by 110.4%. The prior quarter beat by -0.46%. Over the last six quarters, Apple has recorded several small beats. These include 107.27% in February 14, 2024.

Shareholding & Insider Activity

eFFECTOR Therapeutics, Inc. has 4.70 million shares outstanding. The public float is 4.67 million shares, elevated short interest at 1.97% of float. This equals 91.62 thousand shares. The short ratio is 0.97 days. Institutional investors hold 2.71% of the float. Insiders own 2.91%. SR ONE CAPITAL MANAGEMENT, LLC holds 1.82 million shares, WORLAND STEPHEN T has 214.98 thousand shares and ROOT JONATHAN D has 127.57 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, eFFECTOR Therapeutics has not generated any revenue. Returns are negative, with ROA at -174.31% and ROE at 617.96%.
On valuation metrics, eFFECTOR Therapeutics trades at a P/E of -0.00, P/S of 0.00 and P/B of -0.00. Liquidity is tight, with a current ratio of 0.77 and quick ratio of 0.77. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -7661.71 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -3.55, supported by a cash flow-to-debt ratio of -1.44.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, eFFECTOR Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $111.00K (margin 0.00%). Operating income was - $33.84M (margin 0.0%). Net income was- $35.81M (EPS - $16.37).
The company ended the quarter with $18.37M in cash and short-term investments, a total debt of $19.45M, and net debt of $4.57M. Total assets were $20.54M, with equity of - $5.80M. Financials further reflected weakness, with operating cash flow of - $29.55M, free cash flow of - $29.65M, and capital expenditures of - $97.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that eFFECTOR Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by September 04, 2026, within a range of $0.00 to $0.00 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by November 19, 2026, with a range of $0.00 to $0.16. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by August 20, 2027, within a range of $0.00 to $0.49.

Key Takeaways

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) shares are down -89.83% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows eFFECTOR Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.62, suggesting 4873233.33% upside. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current eFFECTOR Therapeutics, Inc. (EFTR) stock price?

eFFECTOR Therapeutics, Inc. (OTC: EFTR) stock price is $0.00 in the last trading session. During the trading session, EFTR stock reached the peak price of $0.00 while $0.00 was the lowest point it dropped to. The percentage change in EFTR stock occurred in the recent session was -62.5% while the dollar amount for the price change in EFTR stock was - $0.00.

EFTR's industry and sector of operation?

The OTC listed EFTR is part of Biotechnology industry that operates in the broader Healthcare sector. eFFECTOR Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of EFTR?

Dr. Douglas Warner M.D.
Chief Medical Officer
Dr. Stephen T. Worland Ph.D.
Chief Executive Officer, Pres & Director
Mr. Michael Byrnes M.B.A.
Chief Financial Officer
Dr. Davide Ruggero Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Mayank J. Gandhi M.D.
Chief Bus. Officer
Dr. Siegfried Reich Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board

How EFTR did perform over past 52-week?

EFTR's closing price is 50% higher than its 52-week low of $0.00 where as its distance from 52-week high of $0.01 is -97%.

How many employees does EFTR have?

Number of EFTR employees currently stands at 14.

Link for EFTR official website?

Official Website of EFTR is: https://effector.com

How do I contact EFTR?

EFTR could be contacted at phone 858 925 8215 and can also be accessed through its website. EFTR operates from 142 North Cedros Avenue, Solana Beach, CA 92075, United States.

How many shares of EFTR are traded daily?

EFTR stock volume for the day was 331 shares. The average number of EFTR shares traded daily for last 3 months was 2.59K.

What is the market cap of EFTR currently?

The market value of EFTR currently stands at $1.41K with its latest stock price at $0.00 and 4.7M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	14
Beta	2.44
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

EFTR Company Profile and Key Details

eFFECTOR Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics